CS
KTTAW icon

Clear Street’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Clear Street’s Portfolio KTTAW Stock Details KTTAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-71
Closed -$2 – 875
2025
Q2 		$2 Hold
71
– – ﹤0.01% 675
2025
Q1 		$1 Hold
71
– – ﹤0.01% 577
2024
Q4 		$2 Sell
71
-29
-29% -$1 ﹤0.01% 586
2024
Q3 		$3 Buy
+100
New +$2 ﹤0.01% 711
2023
Q4 		– Sell
-100
Closed -$1 – 894
2023
Q3 		$1 Sell
100
-100
-50% -$2 ﹤0.01% 1114
2023
Q2 		$3 Buy
+200
New +$6 ﹤0.01% 1307

Other funds holding KTTAW

KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Clear Street's KTTAW Position: Q3 2025 in Review

Clear Street sold out of Pasithea Therapeutics Warrants (KTTAW) in Q3 2025, closing a stake of 71 shares — an estimated $2 sold.

Clear Street first reported a position in KTTAW in Q2 2023 and held it in 6 quarters. The position peaked at $3 in Q3 2024. 5 funds tracked by Wall St. Rank hold KTTAW as of Q3 2025.

  • Clear Street reported no remaining Pasithea Therapeutics Warrants position as of Q3 2025 after selling out during the quarter.
  • Clear Street sold 71 Pasithea Therapeutics Warrants shares in Q3 2025, an estimated $2.
  • Clear Street first reported a position in Pasithea Therapeutics Warrants in Q2 2023 and held it in 6 quarters.
  • Clear Street's Pasithea Therapeutics Warrants position peaked at $3 in Q3 2024.
  • 5 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q3 2025.

Based on Clear Street's 13F filing for Q3 2025, filed 14 Nov 2025.